Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Anixa Biosciences Inc
CY71Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Address: 3150 Almaden Expressway, San Jose, CA, United States, 95118
Analytics
Objectif de Cours de WallStreet
8.5 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés CY71
Analyse des dividendes CY71
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes CY71
Valorisation des titres CY71
financières CY71
Résultats | 2019 | Dynamique |